RAM
AZN icon

Roanoke Asset Management’s AstraZeneca AZN Stock Holding History

Roanoke Asset Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-6,598
Closed -$450K – 105
2017
Q2 		$450K Buy
6,598
+1,583
+32% +$103K 0.21% 71
2017
Q1 		$312K Buy
+5,015
New +$292K 0.15% 80

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Roanoke Asset Management's AZN Position: Q3 2017 in Review

Roanoke Asset Management sold out of AstraZeneca (AZN) in Q3 2017, closing a stake of 6,598 shares — an estimated $450K sold.

Roanoke Asset Management first reported a position in AZN in Q1 2017 and held it in 2 quarters. The position peaked at $450K in Q2 2017. 454 funds tracked by Wall St. Rank hold AZN as of Q3 2017.

  • Roanoke Asset Management reported no remaining AstraZeneca position as of Q3 2017 after selling out during the quarter.
  • Roanoke Asset Management sold 6,598 AstraZeneca shares in Q3 2017, an estimated $450K.
  • Roanoke Asset Management first reported a position in AstraZeneca in Q1 2017 and held it in 2 quarters.
  • Roanoke Asset Management's AstraZeneca position peaked at $450K in Q2 2017.
  • 454 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2017.

Based on Roanoke Asset Management's 13F filing for Q3 2017, filed 20 Oct 2017.